Literature DB >> 28549744

Survival after resection of perihilar cholangiocarcinoma in patients with lymph node metastases.

Stefan Buettner1, Jeroen L A van Vugt2, Marcia P Gaspersz2, Robert J S Coelen3, Eva Roos3, Tim A Labeur3, Georgios A Margonis4, Cecilia G Ethun5, Shishir K Maithel5, George Poultsides6, Thuy Tran6, Kamran Idrees7, Chelsea A Isom7, Ryan C Fields8, Bradley A Krasnick8, Sharon M Weber9, Ahmed Salem9, Robert C G Martin10, Charles R Scoggins10, Perry Shen11, Harveshp D Mogal11, Carl Schmidt12, Eliza Beal12, Ioannis Hatzaras13, Rivfka Shenoy13, Jan N M IJzermans2, Thomas M van Gulik3, Timothy M Pawlik4, Bas Groot Koerkamp14.   

Abstract

BACKGROUND: The aim of this study was to compare patients with PHC with lymph node metastases (LN+) who underwent a resection with patients who did not undergo resection because of locally advanced disease at exploratory laparotomy.
METHODS: Consecutive LN+ patients who underwent a resection for PHC in 12 centers were compared with patients who did not undergo resection because of locally advanced disease at exploratory laparotomy in 2 centers.
RESULTS: In the resected cohort of 119 patients, the median overall survival (OS) was 19 months and the estimated 1-, 3- and 5-year OS was 69%, 27% and 13%, respectively. In the non-resected cohort of 113 patients, median OS was 12 months and the estimated 1-, 3- and 5-year OS was 49%, 7%, and 3%, respectively. OS was better in the resected LN+ cohort (p < 0.001). Positive resection margin (hazard ratio [HR]: 1.54; 95%CI: 0.97-2.45) and lymphovascular invasion (LVI) (HR: 1.71; 95%CI: 1.09-2.69) were independent poor prognostic factors in the resected cohort.
CONCLUSION: Patients with PHC who underwent a resection for LN+ disease had better OS than patients who did not undergo resection because of locally advanced disease at exploratory laparotomy. LN+ PHC does not preclude 5-year survival after resection.
Copyright © 2017 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28549744      PMCID: PMC5907486          DOI: 10.1016/j.hpb.2017.04.014

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  24 in total

Review 1.  Intrahepatic cholangiocarcinoma: management options and emerging therapies.

Authors:  Rebecca M Dodson; Matthew J Weiss; David Cosgrove; Joseph M Herman; Ihab Kamel; Robert Anders; Jean-Francois H Geschwind; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2013-07-24       Impact factor: 6.113

Review 2.  Defining Post Hepatectomy Liver Insufficiency: Where do We stand?

Authors:  Kelly Lafaro; Stefan Buettner; Hadia Maqsood; Doris Wagner; Fabio Bagante; Gaya Spolverato; Li Xu; Ihab Kamel; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2015-06-11       Impact factor: 3.452

Review 3.  Imaging of perihilar cholangiocarcinoma.

Authors:  Marc Rudi Engelbrecht; Seth S Katz; Thomas M van Gulik; Johan S Laméris; Otto M van Delden
Journal:  AJR Am J Roentgenol       Date:  2015-04       Impact factor: 3.959

Review 4.  Outcomes in biliary malignancy.

Authors:  Bas Groot Koerkamp; Yuman Fong
Journal:  J Surg Oncol       Date:  2014-10       Impact factor: 3.454

Review 5.  Resection of Perihilar Cholangiocarcinoma.

Authors:  Hermien Hartog; Jan N M Ijzermans; Thomas M van Gulik; Bas Groot Koerkamp
Journal:  Surg Clin North Am       Date:  2016-04       Impact factor: 2.741

6.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

Review 7.  Cholangiocarcinoma: from molecular biology to treatment.

Authors:  Ana F Brito; Ana M Abrantes; João C Encarnação; José G Tralhão; Maria F Botelho
Journal:  Med Oncol       Date:  2015-10-01       Impact factor: 3.064

8.  Hilar cholangiocarcinoma: diagnosis and staging.

Authors:  William Jarnagin; Corinne Winston
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

9.  Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver.

Authors:  H Bismuth; M B Corlette
Journal:  Surg Gynecol Obstet       Date:  1975-02

10.  Surgical treatment of cholangiocellular carcinoma.

Authors:  R Pichlmayr; P Lamesch; A Weimann; G Tusch; B Ringe
Journal:  World J Surg       Date:  1995 Jan-Feb       Impact factor: 3.352

View more
  10 in total

1.  Surgical Site Infection Is Associated with Tumor Recurrence in Patients with Extrahepatic Biliary Malignancies.

Authors:  Stefan Buettner; Cecilia G Ethun; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Matthew Weiss; Ryan C Fields; Bradley Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles R Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Bas Groot Koerkamp; Shishir K Maithel; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2017-09-14       Impact factor: 3.452

2.  Preoperative Osteopenia Is Associated with Significantly Shorter Survival in Patients with Perihilar Cholangiocarcinoma.

Authors:  Jun Watanabe; Atsushi Miki; Yasunaru Sakuma; Kentaro Shimodaira; Yuichi Aoki; Yoshiyuki Meguro; Kazue Morishima; Kazuhiro Endo; Hideki Sasanuma; Alan Kawarai Lefor; Takumi Teratani; Noriyoshi Fukushima; Joji Kitayama; Naohiro Sata
Journal:  Cancers (Basel)       Date:  2022-04-28       Impact factor: 6.575

3.  Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry.

Authors:  Lynn E Nooijen; Jesus M Banales; Marieke T de Boer; Chiara Braconi; Trine Folseraas; Alejandro Forner; Waclaw Holowko; Frederik J H Hoogwater; Heinz-Josef Klümpen; Bas Groot Koerkamp; Angela Lamarca; Adelaida La Casta; Flora López-López; Laura Izquierdo-Sánchez; Alexander Scheiter; Kirsten Utpatel; Rutger-Jan Swijnenburg; Geert Kazemier; Joris I Erdmann
Journal:  Cancers (Basel)       Date:  2022-05-12       Impact factor: 6.575

Review 4.  Surgical Therapy for Perihilar Cholangiocarcinoma: State of the Art.

Authors:  Lynn E Nooijen; Rutger-Jan Swijnenburg; Heinz-Josef Klümpen; Joanne Verheij; Geert Kazemier; Thomas M van Gulik; Joris I Erdmann
Journal:  Visc Med       Date:  2021-01-07

5.  Low skeletal muscle mass is associated with increased hospital expenditure in patients undergoing cancer surgery of the alimentary tract.

Authors:  Jeroen L A van Vugt; Stefan Buettner; Stef Levolger; Robert R J Coebergh van den Braak; Mustafa Suker; Marcia P Gaspersz; Ron W F de Bruin; Cornelis Verhoef; Casper H C van Eijck; Niek Bossche; Bas Groot Koerkamp; Jan N M IJzermans
Journal:  PLoS One       Date:  2017-10-31       Impact factor: 3.240

6.  Survival rates are higher in married patients with biliary tract cancer: a population-based study.

Authors:  Wei Song; Dong-Liu Miao; Lei Chen
Journal:  Oncotarget       Date:  2018-01-11

Review 7.  The clinicopathological factors associated with prognosis of patients with resectable perihilar cholangiocarcinoma: A systematic review and meta-analysis.

Authors:  Zengwei Tang; Yuan Yang; Zhonghong Zhao; Kongyuan Wei; Wenbo Meng; Xun Li
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

8.  A New Staging System Based on the Dynamic Prognostic Nomogram for Elderly Patients With Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.

Authors:  Junmin Wang; Weirui Ren; Chuang Zhang; Xiaoya Wang
Journal:  Front Med (Lausanne)       Date:  2022-05-02

9.  Comparison study for surgical outcomes of right versus left side hemihepatectomy to treat hilar cholangiocellular carcinoma.

Authors:  Seung Soo Hong; Dai Hoon Han; Gi Hong Choi; Jin Sub Choi
Journal:  Ann Surg Treat Res       Date:  2019-12-30       Impact factor: 1.859

10.  Predictors of survival after surgery with curative intent for perihilar cholangiocarcinoma.

Authors:  Joachim Geers; Joris Jaekers; Halit Topal; Raymond Aerts; Cindy Vandoren; Guy Vanden Boer; Baki Topal
Journal:  World J Surg Oncol       Date:  2020-11-03       Impact factor: 2.754

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.